<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">12071</article-id><article-id pub-id-type="doi">10.36691/RJA12071</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Case reports</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинические случаи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">How to fit an antihistamine, taking into account the individual characteristics of the patient: From pharmacokinetics to profiling</article-title><trans-title-group xml:lang="ru"><trans-title>Как подобрать антигистаминное средство с учётом индивидуальных особенностей пациента: от фармакокинетики до профилирования</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3162-2510</contrib-id><contrib-id contrib-id-type="spin">3363-6170</contrib-id><name-alternatives><name xml:lang="en"><surname>Nenasheva</surname><given-names>Natalia M.</given-names></name><name xml:lang="ru"><surname>Ненашева</surname><given-names>Наталья Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>1444031@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3508-9602</contrib-id><contrib-id contrib-id-type="scopus">6503913655</contrib-id><contrib-id contrib-id-type="spin">2922-9398</contrib-id><name-alternatives><name xml:lang="en"><surname>Sebekina</surname><given-names>Oksana V.</given-names></name><name xml:lang="ru"><surname>Себекина</surname><given-names>Оксана Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>Sebekin1@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2682-8108</contrib-id><contrib-id contrib-id-type="scopus">57210586164</contrib-id><contrib-id contrib-id-type="spin">3363-5507</contrib-id><name-alternatives><name xml:lang="en"><surname>Peredelskaya</surname><given-names>Marina Yu.</given-names></name><name xml:lang="ru"><surname>Передельская</surname><given-names>Марина Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>concy1984@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3505-8520</contrib-id><contrib-id contrib-id-type="scopus">57216550550</contrib-id><contrib-id contrib-id-type="spin">2604-1922</contrib-id><name-alternatives><name xml:lang="en"><surname>Akmalova</surname><given-names>Kristina A.</given-names></name><name xml:lang="ru"><surname>Акмалова</surname><given-names>Кристина Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Assistant of the Department of Clinical Pharmacology</p></bio><bio xml:lang="ru"><p>ассистент кафедры клинической фармакологии</p></bio><email>kriistinkaa@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">Российская медицинская академия непрерывного профессионального образования</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">City Clinical Hospital No. 24</institution></aff><aff><institution xml:lang="ru">Городская клиническая больница № 24</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-06-27" publication-format="electronic"><day>27</day><month>06</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-07-09" publication-format="electronic"><day>09</day><month>07</month><year>2023</year></pub-date><volume>20</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>218</fpage><lpage>228</lpage><history><date date-type="received" iso-8601-date="2023-06-07"><day>07</day><month>06</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-06-16"><day>16</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Фармарус Принт Медиа</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-07-09"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/12071">https://rusalljournal.ru/raj/article/view/12071</self-uri><abstract xml:lang="en"><p>The authors of the article describe the dependence of the effectiveness of any drug on the "correctness" of its choice for the patient and conclude that patient profiling can serve as an effective clinical method for selecting optimal therapy. When prescribing antihistamines, it is suggested to use the following main patient profiles: children, working adults, elderly patients. Each profile has its own specific purpose.</p> <p>The article presents own clinical experience of using fexofenadine based on patient profiling. Cases of fexofenadine therapy in patients with allergic rhinitis and chronic urticaria are given as specific examples. Fexofenadine has an optimal safety profile with minimal impact on concentration and cognitive abilities. In this regard, it can be recommended to employees whose activities are associated with the speed of psychomotor reactions, schoolchildren and university students, elderly patients with high drug load and comorbidity.</p> <p>The article discusses approaches to choosing the optimal second-generation antihistamine in patients of these groups seeking primary medical care when symptoms of urticaria and allergic rhinitis occur.</p></abstract><trans-abstract xml:lang="ru"><p>Авторы статьи описывают зависимость эффективности любого лекарственного препарата от «правильности» его выбора для пациента и делают вывод, что профилирование пациентов может служить действенным клиническим методом подбора оптимальной терапии. При назначении антигистаминных препаратов предлагают использовать следующие основные профили пациентов: дети, работающие взрослые, пожилые пациенты. Каждый профиль имеет свои особенности назначения.</p> <p>В статье приводится собственный клинический опыт использования фексофенадина на основании профилирования пациентов. В качестве конкретных примеров приведены случаи терапии фексофенадином пациентов с аллергическим ринитом и хронической крапивницей. Фексофенадин имеет оптимальный профиль безопасности с минимальным влиянием на концентрацию внимания и когнитивные способности, в связи с чем он может быть рекомендован работникам, деятельность которых связана со скоростью психомоторных реакций, школьникам и студентам вузов, пожилым пациентам, имеющим высокую лекарственную нагрузку и коморбидность.</p> <p>В статье рассматриваются подходы к выбору оптимального антигистаминного препарата второго поколения у пациентов, обращающихся за первичной медицинской помощью при возникновении симптомов крапивницы и аллергического ринита.</p></trans-abstract><kwd-group xml:lang="en"><kwd>fexofenadine</kwd><kwd>patient profiling</kwd><kwd>urticaria</kwd><kwd>allergic rhinitis</kwd><kwd>pharmacokinetics</kwd><kwd>pharmacogenetics</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>фексофенадин</kwd><kwd>профилирование пациентов</kwd><kwd>крапивница</kwd><kwd>аллергический ринит</kwd><kwd>фармакокинетика</kwd><kwd>фармакогенетика</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Brozek G, Lawson J, Szumilas D, Zejda J. Increasing prevalence of asthma, respiratory symptoms, and allergic diseases: Four repeated surveys from 1993–2014. Respir Med. 2015;109(8): 982–990. doi: 10.1016/j.rmed.2015.05.010</mixed-citation><mixed-citation xml:lang="ru">Brozek G., Lawson J., Szumilas D., Zejda J. Increasing prevalence of asthma, respiratory symptoms, and allergic diseases: Four repeated surveys from 1993–2014 // Respir Med. 2015. Vol. 109, N 8. Р. 982–990. doi: 10.1016/j.rmed.2015.05.010</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Baiardini I, Braido F, Brandi S, Canonica GW. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol. 2006;97(4):419–476. doi: 10.1016/S1081-1206(10)60928-3</mixed-citation><mixed-citation xml:lang="ru">Baiardini I., Braido F., Brandi S., Canonica G.W. Allergic diseases and their impact on quality of life // Ann Allergy Asthma Immunol. 2006. Vol. 97, N 4. Р. 419–476. doi: 10.1016/S1081-1206(10)60928-3</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Yanai K, Watanabe T, Yokoyama H, et al. Histamine H1 receptors in human brain visualized in vivo by [11C]doxepin and positron emission tomography. Neurosci Lett. 1992;137(2):145–148. doi: 10.1016/0304-3940(92)90390-s</mixed-citation><mixed-citation xml:lang="ru">Yanai K., Watanabe T., Yokoyama H., et al. Histamine H1 receptors in human brain visualized in vivo by [11C]doxepin and positron emission tomography // Neurosci Lett. 1992. Vol. 137, N 2. Р. 145–148. doi: 10.1016/0304-3940(92)90390-s</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Kawauchi H, Yanai K, Wang DY, et al. Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. Int J Mol Sci. 2019;20(1):213. doi: 10.3390/ijms20010213</mixed-citation><mixed-citation xml:lang="ru">Kawauchi H., Yanai K., Wang D.Y., et al. Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties // Int J Mol Sci. 2019. Vol. 20, N 1. Р. 213. doi: 10.3390/ijms20010213</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Miligkos M, Dakoutrou M, Statha E, et al. Newer-generation antihistamines and the risk of adverse events in children: A systematic review. Pediatr Allergy Immunol. 2021;32(7):1533–1558. doi: 10.1111/pai.13522</mixed-citation><mixed-citation xml:lang="ru">Miligkos M., Dakoutrou M., Statha E., et al. Newer-generation antihistamines and the risk of adverse events in children: A systematic review // Pediatr Allergy Immunol. 2021. Vol. 32, N 7. Р. 1533–1558. doi: 10.1111/pai.13522</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Tashiro M, Sakurada Y, Iwabuchi K, et al. Central effects of fexofenadine and cetirizine: Measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol. 2004;44(8):890–900. doi: 10.1177/0091270004267590</mixed-citation><mixed-citation xml:lang="ru">Tashiro M., Sakurada Y., Iwabuchi K., et al. Central effects of fexofenadine and cetirizine: Measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography // J Clin Pharmacol. 2004. Vol. 44, N 8. Р. 890–900. doi: 10.1177/0091270004267590</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Baharudin A, Latiff AH, Woo K, et al. Using patient profiles to guide the choice of antihistamines in the primary care setting In Malaysia: Expert consensus and recommendations. Ther Clin Risk Manag. 2019;(15):1267–1275. doi: 10.2147/TCRM.S221059</mixed-citation><mixed-citation xml:lang="ru">Baharudin A., Latiff A.H., Woo K., et al. Using patient profiles to guide the choice of antihistamines in the primary care setting in Malaysia: Expert consensus and recommendations // Ther Clin Risk Manag. 2019. N 15. Р. 1267–1275. doi: 10.2147/TCRM.S221059</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Blaiss MS; Allergic Rhinitis in Schoolchildren Consensus Group. Allergic rhinitis and impairment issues in schoolchildren: A consensus report. Curr Med Res Opin. 2004;20(12):1937–1952. doi: 10.1185/030079904x13266</mixed-citation><mixed-citation xml:lang="ru">Blaiss M.S.; Allergic Rhinitis in Schoolchildren Consensus Group. Allergic rhinitis and impairment issues in schoolchildren: A consensus report // Curr Med Res Opin. 2004. Vol. 20, N 12. Р. 1937–1952. doi: 10.1185/030079904x13266</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">May JR, Dolen WK. Management of allergic rhinitis: A review for the community pharmacist. Clin Ther. 2017;39(12):2410–2419. doi: 10.1016/j.clinthera.2017.10.006</mixed-citation><mixed-citation xml:lang="ru">May J.R., Dolen W.K. Management of allergic rhinitis: A review for the community pharmacist // Clin Ther. 2017. Vol. 39, N 12. Р. 2410–2419. doi: 10.1016/j.clinthera.2017.10.006</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: A GA(2)LEN position paper. Allergy. 2010;65(4):459–466. doi: 10.1111/j.1398-9995.2009.02325.x</mixed-citation><mixed-citation xml:lang="ru">Church M.K., Maurer M., Simons F.E., et al. Risk of first-generation H(1)-antihistamines: A GA(2)LEN position paper // Allergy. 2010. Vol. 65, N 4. Р. 459–466. doi: 10.1111/j.1398-9995.2009.02325.x</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J. 2014;44(4):1055–1068. doi: 10.1183/09031936.00059814</mixed-citation><mixed-citation xml:lang="ru">Divo M.J., Martinez C.H., Mannino D.M. Ageing and the epidemiology of multimorbidity // Eur Respir J. 2014. Vol. 44, N 4. Р. 1055–1068. doi: 10.1183/09031936.00059814</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Slavin RG. Treating rhinitis in the older population: Special considerations. Allergy Asthma Clin Immunol. 2009;5(1):9. doi: 10.1186/1710-1492-5-9</mixed-citation><mixed-citation xml:lang="ru">Slavin R.G. Treating rhinitis in the older population: special considerations // Allergy Asthma Clin Immunol. 2009. Vol. 5, N 1. Р. 9. doi: 10.1186/1710-1492-5-9</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Maeda T, Babazono A, Nishi T. Surveillance of first-generation H1-antihistamine use for older patients with dementia in Japan: A retrospective cohort study. Curr Gerontol Geriatr Res. 2018;2018:3406210. doi: 10.1155/2018/3406210</mixed-citation><mixed-citation xml:lang="ru">Maeda T., Babazono A., Nishi T. Surveillance of first-generation H1-antihistamine use for older patients with dementia in Japan: A retrospective cohort study // Curr Gerontol Geriatr Res. 2018. Vol. 2018. Р. 3406210. doi: 10.1155/2018/3406210</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160. doi: 10.1111/j.1398-9995.2007.01620.x</mixed-citation><mixed-citation xml:lang="ru">Bousquet J., Khaltaev N., Cruz A.A., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) // Allergy. 2008. Vol. 63, Suppl. 86. Р. 8–160. doi: 10.1111/j.1398-9995.2007.01620.x</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Huang CZ, Jiang ZH, Wang J, et al. Antihistamine effects and safety of fexofenadine: A systematic review and Meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019;20(1):72. doi: 10.1186/s40360-019-0363-1</mixed-citation><mixed-citation xml:lang="ru">Huang C.Z., Jiang Z.H., Wang J., et al. Antihistamine effects and safety of fexofenadine: A systematic review and Meta-analysis of randomized controlled trials // BMC Pharmacol Toxicol. 2019. Vol. 20, N 1. Р. 72. doi: 10.1186/s40360-019-0363-1</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Fridlyand DG. Individualized assessment of the patient’s sensitivity to the antihistamine, protiovallergic and therapeutic effects of modern H1 antagonists [dissertation abstract]. Moscow; 2002. 34 р. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Фридлянд Д.Г. Индивидуализированная оценка чувствительности пациента к противогистаминному, противоаллергическому и лечебному действию современных H1-антагонистов: Автореф. дис. … канд. мед. наук. Москва, 2002. 34 с.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Church MK, Church DS. Pharmacology of antihistamines. Indian J Dermatol. 2013;58(3):219–224. doi: 10.4103/0019-5154.110832</mixed-citation><mixed-citation xml:lang="ru">Church M.K., Church D.S. Pharmacology of antihistamines // Indian J Dermatol. 2013. Vol. 58, N 3. Р. 219–224. doi: 10.4103/0019-5154.110832</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Pratt C, Brown AM, Rampe D, et al. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy. 1999;29(Suppl 3):212–216. doi: 10.1046/j.1365-2222.1999.0290s3212.x</mixed-citation><mixed-citation xml:lang="ru">Pratt C., Brown A.M., Rampe D., et al. Cardiovascular safety of fexofenadine HCl // Clin Exp Allergy. 1999. Vol. 29, Suppl. 3. Р. 212–216. doi: 10.1046/j.1365-2222.1999.0290s3212.x</mixed-citation></citation-alternatives></ref></ref-list></back></article>
